1. Home
  2. PDD vs VRTX Comparison

PDD vs VRTX Comparison

Compare PDD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PDD

PDD Holdings Inc.

HOLD

Current Price

$81.35

Market Cap

134.5B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$445.17

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDD
VRTX
Founded
2015
1989
Country
Ireland
United States
Employees
N/A
N/A
Industry
Business Services
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
134.5B
115.7B
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
PDD
VRTX
Price
$81.35
$445.17
Analyst Decision
Buy
Buy
Analyst Count
9
29
Target Price
$139.22
$539.69
AVG Volume (30 Days)
9.7M
1.1M
Earning Date
05-26-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
836.54
EPS
N/A
4.02
Revenue
N/A
$2,488,652,000.00
Revenue This Year
$15.35
$10.79
Revenue Next Year
$12.63
$10.47
P/E Ratio
$10.63
$108.35
Revenue Growth
N/A
46.20
52 Week Low
$81.00
$362.50
52 Week High
$139.41
$509.98

Technical Indicators

Market Signals
Indicator
PDD
VRTX
Relative Strength Index (RSI) 32.23 54.29
Support Level N/A $429.02
Resistance Level $106.47 $461.66
Average True Range (ATR) 2.89 9.92
MACD -0.59 0.80
Stochastic Oscillator 13.09 77.74

Price Performance

Historical Comparison
PDD
VRTX

About PDD PDD Holdings Inc.

PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: